North of Tyne and Gateshead Guidelines for Management and Diagnosis of Hypertension Reviewed August 2017
|
|
- Conrad Preston
- 5 years ago
- Views:
Transcription
1 North of Tyne and Gateshead Guidelines for Management and Diagnosis of Hypertension Reviewed August 2017 An electronic version of this document can also be viewed / downloaded from the North of Tyne and Gateshead Area Prescribing Committee Website at: Endorsed for use within North Tyneside, Northumberland, Newcastle and Gateshead by the North of Tyne and Gateshead APC Medicines October Use and 2017 Guideline Group recommended review Review date Membership of the guideline development group date: August 2020 Dr J Skinner, Consultant Community Cardiologist, NuTH guideline co-ordinator Dr S Bennett, Consultant Physician and Diabetologist, NHCT Dr R Curless, Consultant Physician with interest in Stroke Medicine, NHCT Dr A Dixit, Consultant in Stroke Medicine, NuTH Dr P Dorman, Consultant Neurologist, NuTH Dr A Dyker, Consultant in Clinical Pharmacology and Stroke, NuTH Dr S Eaton, Consultant in Diabetes, NDr D Higham, Consultant Cardiologist, NHCT Dr S Kirk, GP, Newcastle and Gateshead CCG. Dr S Little, Consultant in Diabetes, NuTH Mr M Lowery, Formulary Pharmacist, NuTH Prof S Marshall, Consultant in Diabetes, NuTH Dr F Naylor, GP, Northumberland CCG Dr C Runnett, Consultant Cardiologist, NHCT Dr Caroline Sprake, GP, North Tyneside CCG Prof G Stansby, Consultant in Vascular Surgery, NuTH Dr C Tomson, Consultant Nephrologist, NuTH Professor S Thomas, Consultant in Clinical Pharmacology, NuTH Mrs S Turner, Medicines Optimisation, NECS 1
2 Contents Introduction 3 Diagnosis of hypertension summary 4 Management of hypertension summary 5 Antihypertensive drug treatment summary 6 Additional notes 7 Appendices Examples of drug costs 9 Membership of the guideline group 10 Page 2
3 Introduction This guidance is for the diagnosis and management of hypertension. In particular it summarises and interprets the NICE guideline for the clinical management of primary hypertension in adults, the two NICE guidelines for Type 1 and Type 2 diabetes, and the NICE guideline for CKD for local implementation. However, it does not rewrite the NICE guidelines with which clinicians should also be familiar. These guidelines are intended for all clinicians in the Newcastle, North Tyneside, Northumberland and Gateshead areas involved in the diagnosis and management of hypertension. Some top tips for managing patients with hypertension Ensure blood pressure is measured correctly on each occasion (see Diagnosis of hypertension flowchart). Consider reducing the dose of a drug, rather than stopping, if there are problems with tolerability. Moderate doses of more than one agent may be more effective than maximum dose of a single agent. Agree a schedule with the patient for monitoring effectiveness and safety of treatment and for titration of medication to optimise management as part of the initial shared decision making about management with the patient. Medication to control blood pressure to target should be titrated every 4 to 6 weeks. Monitoring blood tests (egfr and serum electrolytes) should be checked 2 weeks after initiating or increasing the dose of ACE inhibitors or ARBs. How to use the guidelines The guideline is presented as three summary flow charts: diagnosis of hypertension, management of hypertension and antihypertensive drug treatment, with additional notes thereafter. Hyperlinks are included from the index and the flow charts can also be printed and laminated for easy reference if preferred. The BNF and the North of Tyne Formulary should be referred to as appropriate. Patient information There are a variety of resources available for patients. None are specifically endorsed by the group, but clinicians may find some of the following useful to share with patients. Blood Pressure UK; HBPM; asure d.pdf The guideline development group recognise and fully support the importance of shared decision making with patients and will signpost to additional resources as these are identified, but it is beyond the scope of this guideline to include detailed information within this guideline. 3
4 Diagnosis of hypertension Patient information and education Provide information and education in an appropriate format to support patients to make informed decisions about their treatment for hypertension and to lower cardiovascular risk at each step in the diagnostic and management pathway Patient being assessed for possible hypertension Measure blood pressure in both arms If difference between the 2 arms > 20 mmhg repeat If difference remains > 20 mmhg, record which arm is higher and use thereafter 1 If BP 140/ 90 mmhg Make a second measurement If second measurement substantially different to first, make a third 2 Record lower of last two measurements as clinic blood pressure Notes 1 Consider including on primary care template which to use for subsequent measurements if BP different between arms 2 BP should be measured after 5 minutes rest 2 or 3 times, with 2 minutes between. Consider additional measurements if successive BP measurements are substantially different and BP still falling. 3 ABPM: at least 2 measurements / hour during normal waking hours with average HBPM: person seated, 2 measurements at least 1 minute apart, and BP recorded twice daily (ideally morning and evening), and for at least 4 days, ideally 7 days. Discard measurements on day 1, average all remaining for result of HBPM Refer for same day specialist care if: Accelerated hypertension (papilloedema/ retinal haemorrhage) or Suspected phaeochromocytoma (labile or postural hypotension, headache, palpitations, pallor, diaphoresis) or Suspected hypertensive encephalopathy (confusion, visual loss, with severe hypertension) Clinic blood pressure < 140/ < 90 mmhg Clinic blood pressure 140/90 180/110 mmhg Clinic blood pressure 180/ 110 mmhg Indication to start antihypertensive treatment same day? No Offer ambulatory blood pressure monitoring (ABPM) 3 If ABPM not tolerated or refused, offer home blood pressure monitoring (HBPM) 4 Arrange investigations for target organ damage (kidney, LVH, consider fundoscopy) Assess 10 year cardiovascular risk Yes Start treatment Severe hypertension ABPM / HBPM < 135/ < 85 mmhg ABPM / HBPM 135/ 85 < 150/ < 95 mmhg Diagnose Stage 1 hypertension ABPM / HBPM 150/ 95 mmhg Diagnose Stage 2 hypertension Normotensive If evidence of target organ damage and or high cardiovascular risk, manage appropriately, otherwise check BP at least every 5 years No diabetes / CKD with ACR 70 mg/mmol/l (at all times) Diagnosis: clinic BP 140/ 90 mmhg, ABPM / HBPM 135/ 85 mmhg Type 2 Diabetes no kidney, eye or cerebrovascular damage Diagnosis: 140/ 80 mmhg, ABPM / HBPM 135/ 75 mmhg Type 1 Diabetes if no renal damage and < 2 features of the metabolic syndrome Diagnosis: 135 / 85 mmhg, ABPM / HBPM 120 / 80 mmhg Others with diabetes, and all patients with CKD and ACR > 70 mg/mmol/l (at any time) Diagnosis: clinic BP 130/ 80 mmhg, ABPM / HBPM 125/ 75 mmhg In some patients, for example those with ACR 70 mg/mmol/l, diabetic retinopathy, lower thresholds may be considered clinically appropriate and management individualised. Management of hypertension 4
5 Patient information and education Provide information and education in an appropriate format to support patients to make informed decisions about their treatment for hypertension and to lower cardiovascular risk at each step in the diagnostic and management pathway All patients diagnosed with hypertension Assess Cardiovascular risk (refer to FATS) Measure Urine protein quantification (ACR), use reagent strip for haematuria Blood sample: HbA1c, electrolytes, creatinine, egfr, total and HDL cholesterol Consider examining fundi for retinopathy 12 lead ECG for LVH Lifestyle advice (offer appropriate information and interventions to support changes) Healthy eating, including reducing salt Increase physical activity Quit smoking Alcohol within safe limits Discourage excessive coffee / caffeine rich products Review results of ABPM / HBPM Consider specialist referral Patients aged < 40 years, before starting drug treatment Patients with particularly severe hypertension (eg 220/120 but without features of accelerated hypertension) Complicated hypertension (eg with TIA, heart failure) Possible underlying causes: including primary aldosteronidism (hypokalemia +/- high normal plasma sodium), phaeochromocytoma (labile or postural hypotension, headache, palpitations, pallor, diaphoresis) Suspected renal hypertension (see local CKD guidelines) Sudden worsening / rapidly progressive hypertension Drug resistant hypertension (not controlled by three drugs or more) Therapeutic problems preventing blood pressure control (drug intolerance etc) ABPM / HBPM 135/ 85 < 150/ < 95 mmhg Stage 1 hypertension ABPM / HBPM 150/ 95 mmhg Stage 2 hypertension 1 Offer drug treatment (see drug flow) if aged < 80 years, and Target organ damage Established cardiovascular disease Renal disease Diabetes 10 year cardiovascular disease risk equivalent 20% Offer drug treatment (see drug flow) Target blood pressure on treatment, aged 80 years 2 No diabetes / CKD Clinic BP < 140/ < 90 mmhg, HBPM / daytime av. ABPM < 135/ < 85 mmhg CKD without diabetes / ACR 70 mg/mmol/l Clinic BP < 140/ < 90 mmhg, HBPM / daytime av. ABPM < 135/ < 85 mmhg Type 2 Diabetes no kidney, eye or cerebrovascular damage Clinic BP < 140/ < 80 mmhg, ABPM / HBPM < 135/ < 75 mmhg Type 1 Diabetes if no renal damage and < 2 features of the metabolic syndrome Clinic BP < 135 / 85 mmhg, ABPM / HBPM < 130 / < 80 mmhg All others with diabetes, and all patients with CKD and ACR > 70 mg/mmol/l (at any time) Clinic BP < 130/ < 80 mmhg, HBPM / daytime av. ABPM < 125/ < 75 mmhg (target range systolic BP mmhg, HBPM / daytime av. ABPM mmhg, unless other comorbidities to consider) Target blood pressure on treatment, aged > 80 years 2 Lower targets can be used, with a target systolic blood pressure 10 mmhg lower in each group above Notes 1 Patients with stage 1 hypertension and no drug treatment should be reviewed annually and offered drug treatment if clinic blood pressure > 160/ > 100 (repeat ABPM / HBPM if uncertainty) and or high risk features (see above) develop 2 Consider repeating ABPM / HBPM on treatment as adjunct to clinic blood pressure measurements to monitor response to treatment if significant white coat effect ie discrepancy > 20/ > 10 mmhg between clinic and average ABPM/HBPM at diagnosis, but not as routine. HBPM may be particularly useful in this circumstance. 3 Patients aged 80 years with previous diagnosis and already treated - do not down-titrate drugs unless postural hypotension is a concern. All patients diagnosed with hypertension should have an annual review to include: Clinic BP (consider HBPM the week before or if the clinic BP > target), ACR, egfr / U&E, review and agree management plan. Refer to other local guidelines for additional monitoring requirements eg FATS, diabetes guidelines, etc Antihypertensive drug treatment 5
6 Aged < 55 years Aged 55 years or black person of African or Caribbean family origin of any age Step 1 ACE inhibitor ARB only if ACE inhibitor not tolerated Calcium channel blocker eg amlodipine 1 indapamide i/r if CCB not tolerated or evidence of heart failure or high risk of heart failure (providing not already treated with a loop diuretic) Step 2 Step 3 Combine A + C Review concordance Titrate drugs to maximum tolerated If additional drug treatment required add 1 indapamide i/r, if not already started in step 1 ie combine A + C + D Patient information and education Provide information and education in an appropriate format to support patients to make informed decisions about their treatment for hypertension and to lower cardiovascular risk at each step in the diagnostic and management pathway Resistant hypertension Step 4 Review concordance with lifestyle and drug treatment Titrate drugs to maximum tolerated doses Consider additional drug treatment: Spironolactone or eplerenone (consider and monitor for risk of hyperkalaemia) Alpha blocker 2 Beta blocker eg atenolol, bisoprolol Do not combine an ACE inhibitor and ARB for treatment of hypertension Try and avoid the combination of an ACE inhibitor / ARB with spironolactone / eplerenone in the absence of HF-REF, particularly in patients at greatest risk of developing hyperkalaemia Seek specialist advice unless circumstances make this inappropriate / unnecessary Notes 1 Appropriate generic preparations of thiazide-like diuretics are now available. Indapamide is substantially less costly than chlorthalidone (see drug costs in the appendix) and is preferred. Patients already treated with bendroflumethiazide and are stable on that, should continue existing treatment, and not be routinely switched. 2 Beta blockers may be considered as initial treatment if Intolerance to ACE inhibitors / ARB Women of child bearing potential Evidence of increased sympathetic drive If treated with a beta blocker, add a CCB, not a thiazide diuretic if additional treatment required, to reduce risk of developing diabetes particularly in those at risk of developing Type 2 diabetes. If the combination of a beta blocker and a thiazide is used consider combining with a potassium sparing diuretic to avoid cellular potassium depletion The BNF and North of Tyne / Gateshead Formulary should be referred to as appropriate 6
7 Additional notes It is assumed that healthcare providers will ensure any device used for measuring blood pressure is appropriately maintained and calibrated, and appropriate cuff sizes for the patients arm are available and used. Healthcare professionals who take blood pressure measurements should be adequately trained and be competent to do so, adhering to the recommendations in the NICE guideline. Palpate the pulse before measuring blood pressure. If the pulse is irregular, consider investigating for atrial fibrillation and measure blood pressure manually using direct auscultation over the brachial artery. Automated devices may not be accurate with an irregular pulse. A difference in blood pressure between the two arms of > 20 mmhg, does not require further investigation unless symptomatic and or aged 50 years. The arm with the higher blood pressure should be used to measure blood pressure and cardiovascular risk managed appropriately. In general, patients should be considered to have peripheral arterial disease and be treated with secondary prevention. Ambulatory blood pressure monitoring (ABPM) is recommended in preference to home blood pressure monitoring (HBPM) for the diagnosis of hypertension, consistent with the NICE guideline and recognising that there is evidence which links the results of ABPM monitoring with cardiovascular risk. The local guideline group recognised that there are inadequate resources at present for all patients to have ABPM or HBPM, but that this should be aspired to in the future. If ABPM (or HBPM) is normal and there is no end organ damage or other high risk conditions such as established cardiovascular disease or diabetes, clinic blood pressure need not be routinely repeated for 5 years. In general, clinicians should avoid measuring ABPM (or HBPM) repeatedly in response to clinic blood pressure measurements, if there is no significant change compared to the initial clinic blood pressure when ABPM (or HBPM) was normal. Previously the North of Tyne APC recommended bendroflumethizide, rather than a thiazide-like diuretic pending appropriate generic preparations becoming available. Indapamide and chlorthalidone preparations are now available. Indapamide is far less costly (see appendix for drug costs) and there was a clinical consensus within the guideline group that the local guideline should now be consistent with the NICE guideline for hypertension and recommend indapamide i/r as a thiazide like diuretic, in patients who are starting a diuretic for hypertension. This approach has been discussed and agreed by the APC. The APC also wished to emphasise that patients who are stable and treated with bendroflumethiazide should in general continue that, and not switch (unless there are clinical indications to do otherwise). Reference to diabetes and CKD is made in the summaries. The diagnostic thresholds and therapeutic targets in the different NICE guidelines as well as in Type 2 diabetes the requirements for the National Diabetes Audit and QOF, mean it is not possible to simplify and harmonise these. When the diastolic blood pressure is lower, it is recognised that in the majority of older people, the lower 7
8 diastolic blood pressure will be easily achieved if the systolic blood pressure target is met. Patients with established cardiovascular disease are high risk and drug treatment of stage 1 hypertension should be considered. Peripheral arterial disease In patients with peripheral arterial disease and claudication, lowering blood pressure may worsen claudication distance and patients should be provided with appropriate information to continue antihypertensive treatment. In patients with critical ischaemia of the leg, the critical ischaemia should be managed initially discuss with vascular surgeons. 8
9 APPENDICES Examples of drug costs Drug Cost per 28 days ( ) Bendroflumethiazide Tabs 2.5 mg od 0.63 Chlorthalidone Tabs 50 mg od Indapamide MR Tabs 1.25 mg od 3.40 Indapamide Tabs 2.5 mg od 1.02 Amlodipine Tabs 5 mg od 0.73 Amlodipine Tabs 10 mg od 0.78 Ramipril Caps 1.25 mg od 1.42 Ramipril Tabs 1.25mg od 1.53 Ramipril Caps 2.5 mg od 1.63 Ramipril Tabs 2.5 mg od 1.13 Ramipril Caps 5 mg od 1.01 Ramipril Tabs 5 mg od 1.00 Ramipril Caps 10 mg od 1.05 Ramipril Tabs 10 mg od 1.16 Lisinopril Tabs 2.5 mg od 0.71 Lisinopril Tabs 5 mg od 0.72 Lisinopril Tabs 10 mg od 0.76 Lisinopril Tabs 20 mg od 0.82 Lisinopril Tabs 40 mg(2x20) od 1.64 Perindopril (erbumine) Tabs 2 mg od 0.98 Perindopril (erbumine) Tabs 4 mg od 1.07 Perindopril (erbumine) Tabs 8 mg od 1.32 Perindopril (arginine) Tabs 2.5mg od 4.43 Perindopril (arginine) Tabs 5 mg od 6.28 Perindopril (arginine) Tabs 10 mg od Losartan Tabs 12.5mg od Losartan Tabs 25mg od 0.80 Losartan Tabs 50 mg od 0.85 Losartan Tabs 100 mg od 1.02 Atenolol Tabs 25 mg od 0.70 Atenolol Tabs 50 mg od 0.72 Atenolol (angina ) Tabs 100mg od 0.76 Bisoprolol (heart failure) Tabs 1.25 mg od 0.86 Bisoprolol (heart failure) Tabs 2.5 mg od 0.78 Bisoprolol (heart failure) Tabs 3.75 mg od 1.05 Bisoprolol Tabs 5 mg od 0.75 Bisoprolol (heart failure) Tabs 7.5 mg od 1.47 Bisoprolol Tabs 10 mg od 0.80 Accessed from NHSBSA Electronic Drug Tariff April 2017, accessed 11/4/2017 9
10 Membership of the guideline development group Dr J Skinner, Consultant Community Cardiologist, Newcastle upon Tyne Hospitals NHS guideline co-ordinator Dr S Bennett, Consultant Physician and Diabetologist, Northumbria Healthcare NHS Dr R Curless, Consultant Physician with interest in Stroke Medicine, Northumbria Healthcare NHS Dr A Dixit, Consultant in Stroke Medicine, Newcastle upon Tyne Hospitals NHS Dr P Dorman, Consultant Neurologist, Newcastle upon Tyne Hospitals NHS Dr A Dyker, Consultant in Clinical Pharmacology and Stroke, Newcastle upon Tyne Hospitals NHS Dr S Eaton, Consultant in Diabetes, Northumbria Healthcare NHS Foundation Trust Dr D Higham, Consultant Cardiologist, Northumbria Healthcare NHS Foundation Trust Dr S Kirk, GP, Newcastle and Gateshead CCG. Dr S Little, Consultant in Diabetes, Newcastle upon Tyne Hospitals NHS Mr M Lowery, Formulary Pharmacist, Newcastle upon Tyne Hospitals NHS Prof S Marshall, Consultant in Diabetes, Newcastle upon Tyne Hospitals NHS Dr F Naylor, GP, Northumberland CCG Dr C Runnett, Consultant Cardiologist, Northumbria Healthcare NHS Foundation Trust Dr Caroline Sprake, GP, North Tyneside Prof G Stansby, Consultant in Vascular Surgery, Newcastle upon Tyne Hospitals NHS Dr C Tomson, Consultant Nephrologist, Newcastle upon Tyne Hospitals NHS Professor S Thomas, Consultant in Clinical Pharmacology, Newcastle upon Tyne Hospitals NHS Mrs S Turner, Medicines Management, North of Tyne Declared conflicts of interest None declared Date of guideline August 2017 Date of review August
5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationClinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127
Hypertension in adults: diagnosis and management Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationHypertension Clinical case scenarios for primary care
Hypertension Clinical case scenarios for primary care Implementing NICE guidance August 2011 NICE clinical guideline 127 What this presentation covers Five clinical case scenarios, including: presentation
More informationVolume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)
Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical
More informationPrimary hypertension in adults
Primary hypertension in adults NICE provided the content for this booklet which is independent of any company or product advertised Hypertension Welcome NICE published an updated guideline on the diagnosis
More informationCVD Risk of Hypertension. Regina Giblin CVD Clinical Development Coordinator
CVD Risk of Hypertension Regina Giblin CVD Clinical Development Coordinator CVD Clinical Development Coordinator In-house education for your team: Regina Giblin giblinr@bhf.org.uk Often interactive with
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationImpact of Recent Hypertension Guidelines on Clinical Practice
C H A P T E R 144 Impact of Recent Hypertension Guidelines on Clinical Practice NK Soni, VB Jindal The movement towards evidence-based healthcare has been gaining ground quickly over the past few years,
More informationNICE BHS Hypertension guidelines 2011 update
NICE BHS Hypertension guidelines 2011 update Review for clinicians Sept 2011 Mark Thomas West Midlands Hypertension Centre Heart of England NHS Trust www.wmhc.co.uk mark.thomas@heartofengland.nhs.uk Full
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationDr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.
Dr Diana R Holdright MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION www.drholdright.co.uk Blood pressure is the pressure exerted on the walls of the arteries when the heart pumps;
More informationIncidental Findings; Management of patients presenting with high BP. Phil Swales
Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental
More informationCKD & HT. Anne-Marie Angus
CKD & HT Anne-Marie Angus Hypertension definitions Persisting BP >140/90 and HBPM >135/85 Stage 1 >140/90 (HBPM >135/85) Stage 2 >160/100 (HBPM >150/90) Severe >180/100 White coat HT Why treat? A major
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationHeart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationHeart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationDudley Hypertension Pathway. Presented for discussion, approval and ratification to
e Dudley Hypertension Pathway Document Description Document Type Clinical Pathway Service Application Diagnosis and Management Version 2.0 Ratification date May 2016 Review date May 2018 Lead Author(s)
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More informationCLINICAL GUIDELINE. Document No:CG38 *All Sites Management of adult patients referred to South Tees University Hospitals for hypertension.
GUIDELINE CLINICAL GUIDELINE Document No:CG38 *All Sites Management of adult patients referred to South Tees University Hospitals for hypertension. TITLE Management of adult patients referred to South
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationCoronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)
CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationHypertension. Clinical management of primary hypertension in adults. Issued: August NICE clinical guideline 127. guidance.nice.org.
Hypertension Clinical management of primary hypertension in adults Issued: August 2011 NICE clinical guideline 127 guidance.nice.org.uk/cg127 NICE has accredited the process used by the Centre for Clinical
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationHigh blood pressure (Hypertension)
High blood pressure (Hypertension) Information for patients from the Department of Renal (Kidney) Medicine This leaflet is not meant to replace the information discussed between you and your doctor, but
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationModule 3.2. Management of hypertension at primary health care
Module 3.2 Management of hypertension at primary health care What s inside Introduction Learning outcomes Topics covered Competency Teaching and learning activities Background information Introduction
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationGuideline scope Hypertension in adults (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Hypertension in adults (update) This guideline will update the NICE guideline on hypertension in adults (CG127). The guideline will be
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationmajor public health burden
HYPERTENSION INTRODUCTION Hypertension is one of the major public health burden in the recent times. Hypertension remains a challenging medical condition among the noncommunicable diseases of ever growing
More informationAdapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017
Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:
More informationCHALLENGES OF HYPERTENSION IN THE COALFACE
CHALLENGES OF HYPERTENSION IN THE COALFACE Y VERIAVA CENTRE FOR RURAL HEALTH SCHOOL OF CLINICAL MEDICINE FACULTY OF HEALTH SCIENCES UNIVERSITY OF WITWATERSRAND SYSTOLIC AND DIASTOLIC BLOOD PRESSURES (BP)
More informationHypertension: Management of hypertension in adults in primary care
Hypertension: Management of hypertension in adults in primary care NICE guideline Second draft for consultation, February 2004 If you wish to comment on the recommendations, please make your comments on
More informationSummary of recommendations
Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationPatient decision aid: Type 2 diabetes blood pressure control
Patient decision aid: Type 2 diabetes blood pressure control What this patient decision aid is for? This decision aid is intended to assist healthcare professionals in consultations with patients who have
More informationHypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN
Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups Lisa Ivy APRN The 2017 Guideline is an Update to JNC7 New information regarding BP related risk of CVD Ambulatory BP monitoring
More informationPRIMARY MANAGEMENT OF DRUG PRESCRIBING IN NON-MALIGNANT PAIN
NORTH OF TYNE GUIDELINES FOR: PRIMARY MANAGEMENT OF DRUG PRESCRIBING IN NON-MALIGNANT PAIN (EXCLUDING DETAILED RECOMMENDATIONS FOR LONG TERM STRONG OPIATES) February 2015 (minor update April 2017) 1 CONTENTS
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationChronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)
Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update) NICE guideline Apendix C The algorithms Draft for consultation, January 2010 Chronic
More informationWhat s New? Hypertension Canada Guidelines for the Management of Hypertension
What s New? 2017 Hypertension Canada Guidelines for the Management of Hypertension What s New? About This Booklet This booklet highlights key advancements and important, enduring aspects of the Hypertension
More informationAtrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency
Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationWhat is Hypertension?
What is Hypertension? What is hypertension? Hypertension is also known as high blood pressure. Our blood needs to be under pressure to make it move around the body, but when it is too high this causes
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationPresentation of hypertensive emergency
Presentation of hypertensive emergency Definitions surrounding hypertensive emergency Hypertension: elevated blood pressure (BP), usually defined as BP >140/90; pathological both in isolation and in association
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationGuidelines for the Prescribing of Sacubitril / Valsartan
Hull & East Riding Prescribing Committee Guidelines for the Prescribing of Sacubitril / Valsartan 1. BACKGROUND Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor, including both a neprilysin
More informationSystemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept
Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept Continents 1- introduction 2- classification/definition 3- classification/etiology 4-etiology in both categories 5- complications
More informationSwindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus 1 Contents Executive Summary... 3 How to Screen for Diabetic Nephropathy... 4 What to Measure... 4 Frequency
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationFrimley Health Area Prescribing Committee
Frimley Health Area Prescribing Committee Frimley Health NHS Foundation Trust North East Hampshire and Farnham CCG East Berkshire CCG Surrey Heath CCG Buckinghamshire CCG SHARED CARE Guideline Amber Traffic
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationOverview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar
Overview 1. Why hypertension is important? 2. What are basic principles in treatment? 3. Different ways of measuring 4. Hypercholesterolemia NOT A REPETION OF LOCAL GUIDELINE CVD risk factors? Non modifiable
More informationACE. Inhibitors. Quiz feedback
ACE Inhibitors Quiz feedback bpac nz better medicin e bpac nz Quiz feedback, ACE inhibitors, 2006 Best Practice Advocacy Centre ACE inhibitors quiz feedback bpac nz Development Team: Rachael Clarke Sonia
More informationInverclyde CHP Protected Learning Event- Heart Failure
Inverclyde CHP Protected Learning Event- Heart Failure 14:00 14:05 14:05 14:20 14:20 14:30 14:30 15:10 15:10 15:30 15:30 15:50 15:50 16:05 16:05 16:35 Welcome & Introduction Paul Forsyth (HF Pharmacist)
More informationManagement of Hypertension and Consequences of non-compliance. Colin Edwards
Management of Hypertension and Consequences of non-compliance Colin Edwards CARDIOLOGIST AHG May 2016 Outline 1. Consequences of poorly controlled hypertension 2. BP targets and anti-hypertensive drugs
More informationIs Traditional Clinic Blood Pressure Dead?
Royal College of Physicans May 16 th 2017 Is Traditional Clinic Blood Pressure Dead? Professor Bryan Williams MD FRCP FAHA FESC Chair of Medicine UCL Director National Institute for Health Research Biomedical
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationTechnical package for cardiovascular disease management in primary health care. Evidence-based treatment protocols
Technical package for cardiovascular disease management in primary health care Evidence-based treatment protocols Technical package for cardiovascular disease management in primary health care Evidence-based
More informationNetwork Hypertension Algorithm
Network Hypertension Algorithm Content Review and Approval: This document is subject to review, revision, and (re)approval by the Clinical Integration and Oversight Committee (CIOC) annually and following
More informationApproach to patient with hypertension. Dr. Amitesh Aggarwal
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationNew indicators to be added to the NICE menu for the QOF and amendments to existing indicators
New indicators to be added to the for the QOF and amendments to existing indicators 1 st September 2015 Version 1.1 This document was originally published on 3 rd August 2015, it has since been updated.
More information